Kyverna Therapeutics, Inc.

EDGAR

Market value

$317.69M

63,221,970 shares as of 2026-11-06, at $5.025 a share (KYTX, IEX close on 2026-11-12) Primary-source evidence

20 filing records in this dataset, filed from 2024-01-16 to 2026-11-12. Reported financial figures are available; chart coverage varies by period.

Watchlist

Holdings and insider activity

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, over the last 12 months.

Window: transactions dated on or after 2025-11-18.

Open-market purchases (code P)
2 transactions, 266,666 shares
Sum of shares × price per share: 1,999,995
Open-market sales (code S)
1 transactions, 23,998 shares
Sum of shares × price per share: 292,775.6

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

  • 2026-05-27 Aktar Mert A 5,093 0
  • 2026-05-27 Aktar Mert A 20,582 0
  • 2026-05-27 Cohen Fred E A 5,093 0
  • 2026-05-27 Cohen Fred E A 20,582 0
  • 2026-05-27 CLARK IAN T A 5,093 0

5% holders (Schedule 13D and 13G)

  • GordonMD Global Investments LP 7.34% SCHEDULE 13G/A 09/30/2026
  • GordonMD Long Biased Master Fund LP 6.79% SCHEDULE 13G/A 09/30/2026
  • GordonMD Long Biased GP LLC 6.79% SCHEDULE 13G/A 09/30/2026

See all insider transactions

Cash and cash equivalents
31.8 million USD Source
Exact value

31818000 USD

Long-term debt including current maturities
Not available
Shares outstanding
62.5 million shares Source
Exact value

62537376 shares

Reported share-count change

42.80% · 18.7 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence
  • 43794087 shares · 2025-09-30· Source
  • 62537376 shares · 2026-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-158 million USD

2025-10-01 – 2026-09-30

Exact inputs and evidence
  • Net income: -161307000 USD · 2025-01-01 – 2025-12-31 Source
  • Net income: -123503000 USD · 2025-01-01 – 2025-09-30 Source
  • Net income: -39728000 USD · 2026-01-01 – 2026-03-31 Source
  • Net income: -38319000 USD · 2026-04-01 – 2026-06-30 Source
  • Net income: -41941000 USD · 2026-07-01 – 2026-09-30 Source

Company performance

Up to ten complete financial years · consolidated figures

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-11-12.

Financial data available through: 2025-12-31.

Coverage by financial measure
  • revenue: No compatible figures in this window
  • Operating income: 3 of 11 periods available· newest 2025-12-31
  • Net income: 3 of 11 periods available· newest 2025-12-31
  • Operating cash flow: 3 of 11 periods available· newest 2025-12-31
  • Capital expenditure: 3 of 11 periods available· newest 2025-12-31
  • Total assets: 3 of 11 periods available· newest 2025-12-31
  • Total liabilities: 3 of 11 periods available· newest 2025-12-31
  • Current assets: 3 of 11 periods available· newest 2025-12-31
  • Current liabilities: 3 of 11 periods available· newest 2025-12-31
  • Cash and cash equivalents: 3 of 11 periods available· newest 2025-12-31
  • long term debt: No compatible figures in this window
  • Shares outstanding: 3 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

  • Net income

    −USD 33.83 million

    Prior period

    −USD 127.48 million

    –

    Current period

    −USD 161.31 million

    –

    Exact inputs and evidence

    -161307000 − -127477000 = -33830000 USD

    -127477000 USD · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    -161307000 USD · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

  • Operating cash flow

    −USD 39.4 million

    Prior period

    −USD 114.3 million

    –

    Current period

    −USD 153.7 million

    –

    Exact inputs and evidence

    -153700000 − -114300000 = -39400000 USD

    -114300000 USD · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    -153700000 USD · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

  • Capital expenditure

    -99.8%

    Prior period

    USD 2.21 million

    –

    Current period

    USD 5,000

    –

    Exact inputs and evidence

    5000 − 2205000 = -2200000 USD

    2205000 USD · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    5000 USD · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

Revenue is not reported for this company, so its costs cannot be shown as a share of it.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Not enough comparable data to show this history.
Values and sources
Revenue values and source evidence
PeriodSeriesValueSource evidence

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.
Values and sources
Revenue growth values and source evidence
PeriodSeriesValueSource evidence

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.
  • Operating margin
  • Net margin
  • Free cash flow margin
Values and sources
Profit margins values and source evidence
PeriodSeriesValueSource evidence

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.
Values and sources
Operating cash flow values and source evidence
PeriodSeriesValueSource evidence

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.
Values and sources
Free cash flow values and source evidence
PeriodSeriesValue(USD)Source evidence

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.
Values and sources
Liabilities to assets values and source evidence
PeriodSeriesValueSource evidence

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.
Values and sources
Current assets to current liabilities values and source evidence
PeriodSeriesValueSource evidence

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
PeriodNet incomeOperating cash flowCapital expenditureFree cash flow
2023 2023-01-01 – 2023-12-31
−USD 60.37 million
Exact value

Exact value: -60366000 USD

2023-01-01 – 2023-12-31: -60366000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 52.4 million
Exact value

Exact value: -52400000 USD

2023-01-01 – 2023-12-31: -52400000 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

USD 621,000
Exact value

Exact value: 621000 USD

2023-01-01 – 2023-12-31: 621000 USD Inspect Capital Expenditure Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 53.02 million
Calculation and evidence

-52400000 − 621000 USD

Exact free cash flow: -53021000 USD

Share or cite

The citation records this snapshot. The page link may show a newer release later.

2024 2024-01-01 – 2024-12-31
−USD 127.48 million
Exact value

Exact value: -127477000 USD

2024-01-01 – 2024-12-31: -127477000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 114.3 million
Exact value

Exact value: -114300000 USD

2024-01-01 – 2024-12-31: -114300000 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

USD 2.21 million
Exact value

Exact value: 2205000 USD

2024-01-01 – 2024-12-31: 2205000 USD Inspect Capital Expenditure Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 116.51 million
Calculation and evidence

-114300000 − 2205000 USD

Exact free cash flow: -116505000 USD

Share or cite

The citation records this snapshot. The page link may show a newer release later.

2025 2025-01-01 – 2025-12-31
−USD 161.31 million
Exact value

Exact value: -161307000 USD

2025-01-01 – 2025-12-31: -161307000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 153.7 million
Exact value

Exact value: -153700000 USD

2025-01-01 – 2025-12-31: -153700000 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

USD 5,000
Exact value

Exact value: 5000 USD

2025-01-01 – 2025-12-31: 5000 USD Inspect Capital Expenditure Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 153.71 million
Calculation and evidence

-153700000 − 5000 USD

Exact free cash flow: -153705000 USD

Share or cite

The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

20 filings · 766 latest values · 766 originally reported values

Dataset published . Source filing dates and reporting periods are shown separately.

Identifiers: 0001994702, 1994702, KYTX, edgar:1994702

Also known as Kyverna Therapeutics, Inc.